Labcorp Holdings Inc. (NYSE:LH) earns fees from routine and specialty medical tests and laboratory services supporting drug development. Physicians, hospitals, and pharmaceutical companies provide different sources of demand, while personalized treatments create opportunities for more sophisticated testing. Capturing that demand requires spending on equipment, technology, and capacity before the resulting cash arrives.
Insider Monkey lists the company in its 12 Best Healthcare Stocks to Buy Now. Its investment question is whether stronger profits can overcome the cash demands of expansion and justify the forward valuation.
Specialty Testing Must Earn Back the Investment
Labcorp Holdings Inc. can spread equipment, logistics, and administrative costs across a broad testing network. Established physician relationships and insurance coverage help direct specimens into that network. Its drug-development laboratories also create opportunities as personalized treatments require specialized tests.
Second-quarter diagnostics organic growth combined 1.8% higher requisition volume with a 1.8% price-and-mix contribution. More activity and better revenue per requisition supported a company-defined non-GAAP adjusted operating margin for the group of 15.8%, up from 15.1%. This provides evidence of service scale translating into better operating economics.
Maintaining that advantage requires investment in automation, scientific capabilities and laboratory capacity. Higher personnel costs partly offset operating improvements. The network deserves valuation credit when additional testing earns more than the cost of expanding and maintaining it.
The Lower Forward Multiple Depends on Stronger Earnings
Labcorp Holdings Inc. carries approximately 16x forward P/E and 26x trailing P/E. Trailing P/E uses past-year earnings; forward P/E uses forecast earnings. The forward valuation is defensible if laboratory productivity supports earnings growth and restores cash generation after investment.
Reported and adjusted earnings provide different starting points. Adding the latest four quarters gives approximately $12.09 in reported EPS, versus $17.49 in company-defined non-GAAP adjusted EPS. Both adjusted EPS and adjusted operating margin exclude amortization, restructuring, acquisition-related expenses, and selected process-improvement costs, among other items. Acquired-intangible amortization reduces reported profit without a corresponding current cash payment, but buying those businesses still consumes capital.
Management expects 2026 adjusted EPS of $18.10–$18.55 for Labcorp Holdings Inc., implying 11.5% growth from 2025 at the midpoint. Higher testing activity, richer mix, and operating efficiencies support that outlook. First-half reported net income rose to $576.5 million from $450.7 million, also benefiting from a tax rate of 18.3%, versus 22.2%, principally because of discrete foreign-entity restructuring benefits. Future earnings need continued operating progress as that tax comparison becomes less helpful.
Cash remains the test of what those earnings are worth. First-half operating cash flow was nearly unchanged at $637 million. Capital expenditure increased to $252.6 million from $203.9 million, explaining almost all the decline in non-GAAP free cash flow, defined as operating cash flow less capital expenditures, to $384.4 million from $435.2 million.
Receivables absorbed $247.1 million, versus $139.9 million previously, while lower accounts payable consumed $150.4 million, versus $80.6 million. More cash was tied up in customer balances and supplier payments. Improved collections would help, but they cannot remove the ongoing investment bill.
The Higher Multiple Requires Better Cash Returns
The current forward P/E of Labcorp Holdings Inc. compares with approximately 14x in September 2024 and 14x at year-end 2025. Investors are paying more for expected earnings than at either observation.
There is a financial basis for some expansion from 2024. Adjusted EPS increased from $14.57 in 2024 to $16.44 in 2025, while annual free cash flow rose from approximately $1.10 billion to $1.21 billion. Diagnostics and central-laboratory growth improved profitability. The business has demonstrated that its network can support rising earnings and cash.
The comparison with year-end 2025 is more demanding. Expected 2026 adjusted EPS growth of 11.5% is slightly below the preceding year’s roughly 13%. The higher multiple therefore requires confidence in the durability and cash value of growth, rather than faster EPS growth alone.
Labcorp Holdings Inc. expects capital expenditure around 4% of revenue during 2027–2029, above approximately 3.1% in 2025. Management targets 8.5%–11.5% annual adjusted EPS growth through 2029, with free-cash-flow growth in line with earnings. Achieving both would support the higher valuation.
That outlook incorporates a potential return of Medicare laboratory reimbursement reductions under PAMA, which links payments to private-payer rates. CMS has published preliminary 2027 rates; final rates remain pending. Lower reimbursement on affected tests could offset volume and specialty-mix gains, pressuring margins and cash returns. Automation and productivity improvements must help absorb that pressure.
The Peer Discount Reflects Real Financial Differences
Quest Diagnostics Incorporated (NYSE:DGX) is the closest operating peer because of its large U.S. diagnostic-testing network. Its approximately 20x forward P/E compares with 16x for Labcorp Holdings Inc., a roughly 17% discount.
Management guidance midpoints imply calendar-2026 adjusted EPS growth of 13.2% for Quest Diagnostics Incorporated, versus 11.5% for the company. Both use company-defined non-GAAP measures. The peer also reported a higher second-quarter adjusted operating margin, 16.5% versus 15.8%, supporting part of its premium, although different business mixes and adjustments affect comparability.
Cash generation provides stronger support for the gap. The peer’s first-half operating cash flow of $875 million less $252 million of capital expenditure left $623 million, versus $633 million a year earlier. After $22 million of distributions to minority partners, $601 million remained before acquisitions and other shareholder distributions.
That compares with $384.4 million of free cash flow at Labcorp Holdings Inc.. Its $142 million cash balance and $5.86 billion debt load also compare less favorably with $626 million and approximately $5.64 billion, respectively, at the peer.
Biopharma laboratories supplied about 22% of first-half revenue, adding exposure to pharmaceutical research budgets. Those services broaden its opportunities but bring different customer spending cycles. A larger range of businesses earns a premium only when it strengthens returns through those cycles.
Capital allocation reinforces the discount. Second-quarter repurchases of $354 million and dividends of $59 million exceeded $314 million of free cash flow before acquisitions. With debt at $5.86 billion, choosing between repurchases and acquisitions requires returns that exceed financing and reinvestment costs. Repurchases can lift EPS while leaving less cash available to fund growth.
Conclusion
Labcorp Holdings Inc. can justify 16x forward P/E if improving profitability produces stronger cash returns. Its network and specialty-testing opportunities support the investment case, while slower expected growth and weaker cash generation help explain its peer discount.
September’s reaffirmed $1.24 billion–$1.36 billion annual free-cash-flow outlook sets the immediate hurdle. Reaching the midpoint requires approximately $916 million in the second half, versus $771 million a year earlier. Sustaining the valuation requires cash growth alongside earnings despite higher capital spending and reimbursement pressure. Another period of rising profits without improved cash conversion would weaken the case.
READ NEXT: Sunbelt Rentals (SUNB) Raises Guidance. Will Higher Fleet Spending Deliver Cash? and Viasat (VSAT) Adds Satellite Capacity. Can it Generate More Cash?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center